PP
APGE

Paloma Partners’s Apogee Therapeutics APGE Stock Holding History

Paloma Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,100
Closed -$201K – 1147
2024
Q2 		$201K Buy
+5,100
New +$248K 0.01% 1002

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Paloma Partners's APGE Position: Q3 2024 in Review

Paloma Partners sold out of Apogee Therapeutics (APGE) in Q3 2024, closing a stake of 5,100 shares — an estimated $201K sold.

Paloma Partners first reported a position in APGE in Q2 2024 and held it in 1 quarter. The position peaked at $201K in Q2 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q3 2024.

  • Paloma Partners reported no remaining Apogee Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 5,100 Apogee Therapeutics shares in Q3 2024, an estimated $201K.
  • Paloma Partners first reported a position in Apogee Therapeutics in Q2 2024 and held it in 1 quarter.
  • Paloma Partners's Apogee Therapeutics position peaked at $201K in Q2 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.